WO1997023502A1 - Vaccin plasmidique contre le virus pseudorabique - Google Patents
Vaccin plasmidique contre le virus pseudorabique Download PDFInfo
- Publication number
- WO1997023502A1 WO1997023502A1 PCT/EP1996/005611 EP9605611W WO9723502A1 WO 1997023502 A1 WO1997023502 A1 WO 1997023502A1 EP 9605611 W EP9605611 W EP 9605611W WO 9723502 A1 WO9723502 A1 WO 9723502A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasmid
- virus
- vaccine
- dna
- animals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to a plasmid vaccine against the pseudorabic virus, also known under the name of Aujeszky's disease virus (ADV), of swine virus of herpes 1 (PHV-1) or of virus he ⁇ ippo-1 Suid ( SHV-1)
- Aujeszky's disease is a viral disease to which most mammals are sensitive
- humans do not seem to be susceptible to this disease
- the agent causing this disease is a double stranded DNA enveloped virus of the family Herpesviridae, subfamily of alpha-herpesvirinae, namely, pseudorabic virus (PRV).
- PRV pseudorabic virus
- the PRV virus genome is formed by a double-stranded DNA molecule of approximately 150 kb and consists of a single long region (UjJ and a single short region (U s ) which is flanked by two reverse repeat sequences, one terminal (TR) and the other internal (IR) (BEN-PORAT, T et al, 1979, Virology 95, p 285-294)
- Aujeszky's disease virus genome contains at least 70 genes
- Transmission of the virus usually occurs by oral, respiratory or direct contact between an infected animal and a healthy animal
- the disease can be fatal and the duration of incubation is variable and between 15 hours and 12 days
- PRV viruses of the strain are used for vaccination of pigs
- This vaccination method gives the vaccine subject good protection which is due to the intracellular action of the living virus. Indeed, living viruses enter cells where viral antigens will be synthesized.
- peptides derived from these viral antigens are present on the surface infected cells in association with the major histocompatibility class I complex (MHC I).
- MHC I major histocompatibility class I complex
- a cytotoxic response can thus be provoked in addition to the humoral response, which induces in the vaccinated subject better protection against the virus.
- viruses are attenuated by mutations, there is a risk that viruses will become pathogenic again by spontaneous mutations or by recombinations with wild-type viruses.
- Vaccinations with live viral agents can also lead, under certain conditions, to the proliferation of live viruses. This proliferation of live viruses, even attenuated, constitutes a risk for more susceptible subjects, such as newborns or pregnant women.
- Another technique developed more recently consists in the use of a non-pathogenic living vector carrying selected genes of the PRV virus.
- M L. VAN DER LEEK et al (The Veterinary Record (1994) 134, p. 13-18) have led to encouraging results with vaccination of pigs against the PRV virus by scarification or by intramuscular injection of a recombinant swine pox virus and PRV virus (rSPV-AD).
- This recombinant was obtained by insertion of the PRV genes coding for the gp50 and gp63 attached to the promoter P 7.5 of the vaccinia virus in the thymidine kinase gene of the SPV virus.
- ROBINSON et al describe in 1993, in Vaccine 1 1, 957-960, immunization of hens against the influenza virus by intravenous, intraperitoneal and subcutaneous injections of plasmid From 28% to 100% of the animals thus immunized resist to a "challenge" by a lethal dose of the virus II it should be noted that the effectiveness strongly depends on the route and the system used for the injection and on a possible pretreatment of the injection site (DANKO et al, Vaccine 12 , 1499-1502 (1994)) GRAHAM JM COX et al have described a method of vaccination of cattle and mice against the BHV-1 virus by injection of plasmid DNA, in J Virol.
- the aim of the present invention is to provide a plasmid vaccine against the PRV virus responsible for Aujeszky's disease
- a vaccine comprising at least one plasmid coding for the glycoprotein glll of the PRV virus or for a protein having the same antigenicity as the glycoprotein glll of the PRV virus and a pharmaceutically acceptable excipient for the latter.
- the plasmid can be produced, according to well-controlled techniques, in bacteria such as E. coli
- the gene introduced into the plasmid does not need to code for the whole glll protein, it is sufficient that it codes for a part or a homologue of the PRV glll protein which has the same antigenicity as the glll c protein. ie the same effect on the immunological system as the glll protein Indeed, only part of the glll protein is identified by the animal's immunological system, the other parts of the protein, although certainly playing a role in the life of the virus, is not essential in the recognition of the protein by the infected organism. Another advantage is that vaccinated animals can easily be distinguished from animals infected with the PRV virus.
- the vaccinated animals develop only antibodies against the glll protein while the animals infected with the PRV virus also develop antibodies against other proteins of the virus.
- the method is safe, because a proliferation of live viruses is not to be feared Since only a well-defined part of the virus genome is injected, there is no infection by viruses and therefore consequently there can be no proliferation of viruses.
- Vaccination with the vaccine according to the present invention can be used as a diagnostic tool because it induces the formation of monospecific antibodies. These antibodies can be used for the detection of the p antigen. ex. during ELISA or other tests.
- a surprising effect of the invention resides in the effectiveness of the immunization against the PRV virus.
- the importance of the glycoprotein glll in immunization is well known, the injection of the purified glll protein does not seem to have any effect. pronounced effect of immunization.
- Z H. BISEIBUTSU et al describe, in the Japanese patent application
- JP 05/246888 a vaccine against the PRV virus, based on purified glycoprotein glll and an oil-based adjuvant This approach is not used on a commercial scale
- a MATSUDA TSUCHIDA et al show in an article published in J Vet med Sci 54 (3) 447-452, 1992, that a mixture of glycoproteins gll, glll and purified gIV injected together with a conventional oil-based adjuvant, confers a better protection in mice against a challenge by virulent PRV viruses than the glycoproteins injected individually.
- the plasmid is the plasmid pEVhisl4gIII.
- the plasmid pEVhisl4gIII has the advantage of comprising a gene conferring resistance to ampicillin, so that the transformed bacteria, having incorporated the plasmid, are easily selected by adding ampicillin in their growth medium.
- the plasmid comprises a gene coding for a protein having the same antigenicity as the glycoprotein gll1 of the PRV virus, inserted into the plasmid so that it is expressed.
- a marker such as a gene conferring resistance to an antibiotic makes it possible to select the bacteria transformed by the plasmid.
- the plasmid may contain, in addition to the gene coding for the glycoprotein glll of the PRV virus or for a protein having the same antigenicity as the glycoprotein glll of the PRV virus, one or more genes coding for cytokines.
- cytokines are known to exert an adjuvant activity on vaccines. Introducing them into the plasmid so that they can be expressed in cells will increase the effectiveness of the vaccine.
- the vaccine also comprises a pharmaceutically acceptable excipient in which the plasmid is incorporated.
- pharmaceutically acceptable excipient refers either to liquid media or to solid media capable of being used as excipient (vehicle) for introducing the plasmid into the animal to be vaccinated. liquids, water, saline, phosphate-saline buffer, solutions containing adjuvants, detergents, stabilizers and transfection promoting substances, liposome, virosome suspensions and emulsions.
- DNA vaccination can possibly be preceded by pretreatment of the vaccination site (eg use of a local anesthetic) in order to improve its effectiveness.
- the present invention also provides a plasmid vaccine against the PRV virus comprising a nucleic acid sequence coding for the glll protein of the PRV virus or for a protein having the same antigenicity as the glycoprotein glll of the PRV virus or a DNA construct comprising a expression cassette including a) a DNA sequence coding for a polypeptide containing at least one antigenic determinant of the glycoprotein glll or an immunogenic fragment thereof, and b) control sequences operatively linked to said coding sequences where said sequence coding can be transcribed and translated in a cell and where said control sequences are homologous or heterologous to said coding sequence.
- the plasmid vaccine contains one or more genes coding for cytokines.
- Example 1 Obtaining a vaccine
- the vaccine was obtained in three stages, comprising the construction of a plasmid (pEVhisHglII) containing the gene for the glycoprotein gll1 of the PRV virus, the production of this plasmid in transformed bacteria and the formulation of the vaccine comprising the plasmid and an excipient pharmaceutically acceptable
- Step A Construction of a plasmid (pEVhisHglII) containing the PRV virus glycoprotein glll gene
- the plasmid DNA pEVhisHglII was obtained from the Institute for Animal Science and Health, (ID DLO, Lelystad, NL) . It includes the PRV virus glycoprotein glll gene, under the control of the HCMV promoter, and the ampicillin resistance marker gene.
- Step B Production of the plasmid in transformed bacteria Preparation of E. cells. coli treated with RbCl.
- plasmid pEVhisHglII 250 ng of plasmid pEVhisHglII were incubated for 10 minutes on ice (at 0 ° C) and then for 5 minutes at 37 ° C The mixture was then transferred into 2 ml of RB medium (1% bactopeptone (w / v ), yeast extract 0 5% (w / v), NaCl 1% (w / v)) and incubated between 30 minutes and 2 hours at 37 ° C with shaking
- the abbreviation% (w / v) represents a percentage expressed by weight per volume
- the pellets were dried under vacuum and taken up in 100 to 200 ⁇ l of water (filtered on Milli Q device, Millipore, USA) without RNAse treatment
- the plasmid DNA was produced in greater quantity according to one of the following two procedures.
- a suspension of E. coli transformed by the plasmid pEVhisl4gIII is incubated for one hour in 2 ml of RB medium and then distributed in 1 to 4 bottles of 400 ml of RB medium containing ampicillin at a rate of 100 ⁇ g / ml
- the cultures were incubated overnight at 37 ° C. with shaking at approximately 150- 200 revolutions per minute
- the cultures were centrifuged in 500 ml Nalgene tubes for 7 minutes at 8,670 g All the centrifugations were carried out in a Beckman model J2-21 centrifuge
- MOPS represents sulfonic acid 3- (N-morpholino) propane
- the solution was recovered in 40 ml Nalgene tubes 14 ml of isopropanol were added at room temperature After stirring, the mixture
- the column was placed on another collection tube and the dissolved sample (1.8 ml) was deposited on top of the resin.
- the column was centrifuged for 12 minutes at 980 g in a "swinging bucket" rotor.
- the plasmid solution collected was divided into two Eppendorf tubes to which 600 ⁇ l of isopropanol were added. After centrifugation for 15 minutes at 18,320 g (SIGMA 2K15 centrifuge), the pellet was washed with 300 ⁇ l of 70% ethanol ( v / v) and dried under vacuum
- the pellet comprising the plasmid DNA is redissolved in 500 ⁇ l of Milli-Q water (Millipore, USA) and kept cold until vaccination
- Step C Formulation of the vaccine comprising the plasmid and a pharmaceutically acceptable excipient
- the pellet of plasmid DNA being redissolved in water, the DNA concentration was determined by deposition on agarose gel and development with ethidium bromide (see "Molecular cloning, a laboratory manual", J
- Example 2 Use of the Plasmid Vaccine in Mice to Stimulate the Induction of an Antibody Response and a Cytotoxic T Cell Response
- the experiment carried out in mice to prove the efficacy of the plasmid vaccine requires the construction of a control plasmid derived from the plasmid pEVhisl4gIII, prior to the immunization of animals and the analysis of the immune response
- Step 1 Construction of a plasmid derived from the plasmid pEVhisHglII by deletion of the coding sequence of the glll gene
- a plasmid derived from the plasmid pEVhisHglII by deletion of the coding sequence of the glycoprotein glll gene was used as a negative control (pEVhisl4gIH ", DNA ")
- This deleted plasmid was obtained in the following way, the plasmid pEVhisHglII was digested with the restriction enzymes Asp 718 and EcoRV.
- the DNA was then processed using T4 DNA polymerase to obtain blunt-ended fragments.
- the DNA thus obtained was ligated using T4 DNA ligase (see "Molecular cloning, a laboratory manual", J Shambrook, EF Fritsch and T Maniatis, Cold Spring Harbor Laboratory Press (1989), ⁇ 1.53 1.73 )
- mice of the inbred Balb / c strain aged 16 to 18 weeks at the first injection, were used
- mice must be inbred to measure cytotoxic T cell responses (CTL) because the compatibility of the major histocompatibility complex (MHC) between cytotoxic T cells and target cells, - 3T3-swiss albino cells (fibroblasts) (haplotype H-2D) -, must be guaranteed
- the target cells were cultured in a DME medium containing 10% (v / v) fetal calf serum
- the plasmid DNA of the plasmid pEVhisHglII containing the gene for the glycoprotein glll of the PRV virus , was used as positive DNA, (DNA + ) while the equivalent plasmid, without the glll gene, (DNA "), was used as a negative control
- Group I comprising 10 mice marked with a colored code, was vaccinated four times, at week 0 (DNA] + ) at week 3 (DNA2 + ), at week 5 (DNA3 + ) and at week 10 ( DNA4 + ) with DNA + Serum, SADN3 4 " , was collected 2 days before the last injection, serum sADN4 + was collected 6 days after the first collection i.e. 5 days after the last injection DNA 4 "
- Week 1 spleen cells were removed and restimulated in vitro CTL tests were performed 4 days later Group 2 also comprising 10 mice marked with a color code, was vaccinated three times, at week 0 (DNA] + ), at week 3 (DNA2 + ) and at week 5 (DNA3 + ) with DNA + Serum, sADN2 + , was taken 2 days before the last injection and serum sADN3 + a was removed at week 9, i.e. 4 weeks after the last DNA3 + injection. At week 9, the spleen cells were restimulated in vitro.
- Group 3 comprising 8 mice marked with a color code, was vaccinated only twice, at week 0 (DNA j + ) and at week 3 (DNA2 4 " ) Serum, sADN2 + , was collected 2 weeks after the last injection and at week 9
- Group 4 or control group, comprising 10 mice marked with a color code, was vaccinated three times with DNA ", at week 0 with 200 ⁇ g of DNA” (DNA] "), at week 2 with 100 ⁇ g (DNA2 ”) and at week 7 with 100 ⁇ g of DNA” (DNA3 ") Serum, SADN2", was taken 2 days before the last injection and SADN3 "serum was taken at week 8 ie 1 week after the last DNA3 injection "
- Group 5 (positive control group), comprising 6 mice, was vaccinated three times with live virus, strain N1A3 M207 (obtained from the Institute for Animal Science and Health, ID-DLO, NL) at a dose of 10 7 PFU (Plate Forming Unit) per mouse and by injection into the necks , at week 0, at week 16 and at week 17 Serum was collected 2 days after the second injection. A mixture of serum from 5 animals was used for the analyzes.
- Step 3 Analysis of the humoral and cellular immune response (CTL test). Depending on the case, the animals were euthanized and the spleen was removed under aseptic conditions between 7 days and up to six weeks after the last DNA injection. Part A - Culture and in vitro restimulation of the effectors
- mice The vaccinated and control mice were euthanized by cervical dislocation and rinsed with alcohol (70% v / v).
- the rats of these animals were placed in a petri dish containing PB S (Gibco) and were crushed in these dishes using nylon gauze and a curved plastic tube.
- DME medium Dulbecco's modified Eagle, Gibco
- penicillin-streptomycin antibiotic solution penicillin at 10,000 U / ml and streptomycin at 10,000 ⁇ g / ml (Gibco)
- the cells were resuspended at 5 x 10 6 cells per ml in this sterile medium.
- the spleen cells are distributed for their cultivation in vitro in 25 cm 3 culture flasks (Falcon) at the rate of 25 x 10 "cells / flask.
- Part of these cells received an in vitro restimulation by adding one of the viral strains mentioned above with a multiplicity of infection (MOI) equal to 2 and the others served as non-restimulated controls.
- MOI multiplicity of infection
- the cells of the histocompatible line (fibroblasts) 3T3-swiss albino (haplotype H-2D) are used as targets
- the CTL test comprises several steps a) The target cells were infected or not infected with a strain of the Aujeszky virus (NIA3 M207) at an MOI equal to 10, the infected cells being designated CV + and the uninfected cells CV "Ninety minutes later, the labeling of the target cells in suspension began (see below - Eu labeling of the cells targets (3T3) in suspension b) As for the effectors cultured in vitro 4 to 7 days (as described above) before, they were taken up in culture flasks, washed 2 x with effector medium and counted to be returned suspended at a rate of 5 x
- Part C - Eu marking of suspended target cells This type of labeling is applicable both for cells growing in suspension and for adherent cells.
- Culture flasks at maximum confluence were used for the different labeling of the 3T3 target cells.
- the culture flask containing the adherent 3T3 target cells was freed from its growth medium and washed 1 x with PB S (Gibco).
- 5 ml of trypsin-EDTA (Gibco) at 37 ° C. were deposited in the flask on the cell mat. After one minute, the cells were removed by short tapping on the flask. The complete detachment achieved, 7 ml of sterile effector medium [described above] were added.
- the counting of living cells was carried out with Blue Trypan (0.4% solution (w / v), Sigma). One ml of this suspension was completed with:
- the upper part of the solution in the tube up to the interface included was recovered.
- the cells were rid of all traces of Ficoll-Paque by a washing with the effector medium. After counting, the cells were resuspended at a concentration of 105 cells / ml.
- 5,000 target cells were placed in a 96-well round-bottom plate in the presence of 100 ⁇ l of effector medium to determine the amount of background noise from the Eu.
- DNA 4 + group 1 animals injected 4 times with DNA 4 " DNA 3 " group 4, animals injected 3 times with DNA "number of repetitions Lysis of uninfected target cells was between 0 and 9% and was not affected by the transition to the Ficoll-Paque gradient.
- the positive control (group 5) both before and after treatment Ficoll presented a significantly positive cell lysis rate. infected targets were increased by passage over Ficoll-Paque for animals immunized with DNA.
- the CTL test Group 2 injected 3 times with DNA 4 "(DNA3 4") did not show any lytic activity.
- the serum was collected twice during the experiment, the last collection being made just before the sacrifice of the animals to obtain the spleen cells for a CTL test, and the antibody responses were measured by :
- the PRV virus seroneutralization test was carried out according to the procedure which is reproduced below.
- PD5 cells SOLVAY-DUPHAPv, NL
- strain viruses Bartha K61 SOLVAY-DUPHAR, NL
- the medium in which the SN test was carried out had the following composition: 340 ml Eagle minimum essential medium (Flow), 100 ml lactalbumin hydrolyzate 2.5% (w / v); 5-10 ml of 5.6% NaHCO3 (w / v) and 50 ml of fetal calf serum (Gibco).
- test serum was diluted in series of 2 in 2 in the medium, the dilutions ranging from 1 2 to 1.4096 (50 ⁇ l of serum + 50 ⁇ l of medium each time), in the 96-well plate with flat bottom (Greiner ) Each sample was tested in duplicate
- the virus was diluted to 100 TCID50 (tissue culture infectious dose at 50%) in 0.05 ml of medium and 50 ⁇ l of this diluted virus solution were added to each well
- the serum mixture / virus was incubated for 24 hours at 37 ° C 50 ⁇ l of the suspension of PD5 cells having a concentration of 4 ⁇ 10 ⁇ cells / ml were added to each serum / virus sample The plates were then incubated at 37 ° C for 5 days
- the virus was checked by incubating a virus sample diluted for 24 hours at 4 ° C and another virus sample for 24 hours at 37 ° C.
- the two virus suspensions were diluted (v / v) with the test medium SN (see above) 1 10, 1 100 and 1 1000 Then 0.05 ml of each dilution of the virus suspensions were added per well using 8 wells for each dilution Then 0.05 ml of medium and 0.05 ml of cell suspension was added.
- the results were interpreted under the microscope after an incubation of 5 days at 37 ° C
- Serum + is a mixture of serum from 10 OF 1 mice having received at 3 weeks 10 ⁇ TCID (tissue culture infectious dosis) of recombinant adenovirus expressing the gD gene intramuscularly and collected 3 weeks later
- Table 3 and Table 4 reproduced below, show the optical density (OD) as a function of the dilutions of the serum
- the positive samples thus identified were tested a second time at variable dilutions (Table 4)
- SADN2 serum from animals injected twice with DNA
- SADN3 serum from animals injected 3 times with DNA
- SADN3 4 serum from animals injected 3 times with DNA
- SADN4 4 serum from animals injected 4 times with DNA 4
- Table 4 ELISA test - optical density (OD) as a function of dilutions of test serum 2
- mice Five groups of ten mice (Charles River, Germany) females of 16 weeks of age of the inbred strain Balb c were used
- Group G 1 (the positive control) was vaccinated using an attenuated virus (strain N1A3 M207) intraperitoneally l ⁇ 7 PFU (plaque-forming units) were used for each mouse This is a very high dose by comparison with the doses used for the vaccination of pigs with the attenuated vaccine strains traditionally used at the dose of 10 ⁇ 5 PFU
- Plasmid DNA vaccination was carried out by intramuscular injection of 100 ⁇ g in 2 times 100 ⁇ l of water / mouse in the hindquarters left and right for several consecutive days
- Group C was vaccinated twice, Friday and Monday respectively
- Group B received four consecutive injections from Wednesday to Monday
- Group A received 6 doses distributed from Monday to the following Monday
- the animals were housed in cages, separated by group and the individuals were individually marked with blue felt
- the serum taken from each animal was coded so as to be able to follow each animal individually with regard to the antibody assay and the protection conferred by the vaccinations. Part B - Analysis of the immune responses
- Example 2 The development of humoral responses was controlled according to the ELISA protocol presented in Example 2 The test for neutralization of serum virus was carried out according to the method described in Example 2
- Serum samples were taken at the start of the immunization period, i.e. 3 days after the last vaccine injection, at the end of the immunization period, i.e. one month after the last injection injection of vaccine and just before the test inoculation with the virulent virus which took place 9 days later Finally, one month after the challenge, serum was taken again Part C - Test inoculation
- mice were exposed to infection with a live virulent virus of the NIA3 strain at the rate of 7,000 PFU in 200 ml per animal injected intraperitoneally.
- Example 4 Induction of protection in mice against challenge inoculation with virulent viruses. For these experiments, the immunization protocol of Example 3 was followed, with the only difference that injections of plasmid DNA were performed every three weeks and that the mice were 19 weeks old.
- the Gl group (positive control) was vaccinated using the attenuated virus (strain NI A3 M207) in the necks with a dose of 10? PFU per mouse
- Four injections of plasmid DNA were carried out intramuscularly in the two hindquarters of groups of mice each comprising 10 animals, marked with a colored code
- mice were exposed to the virulent virus NIA3 at the rate of 7000 PFU / animal, injected intraperitoneally Deaths are recorded during the 15 days following the test and are listed in Table 6 The results show the survival rates expressed as a percentage as a function of the days following the test Table 6 Monitoring of the survival rate of mice after an inoculation of test with virulent viruses
- a group of 3 animals (# 1, 2 and 3) which have not been vaccinated is used as a negative control
- Three animals (# 4, 5 and 6) received a dose of 75 ⁇ g of plasmid, while 3 other pigs (# 7, 8 and 9) received 560 ⁇ g of plasmid on each injection
- the dose of DNA was diluted in 4 ml of PBS buffer (Gibco, USA) and administered in 4 portions of 1 ml at 4 places of inoculation on both sides of the neck and in the center of the left and right hindquarters
- the injection was performed on the using a syringe fitted with a Terumo needle 40 mm long with an opening of 0 9 mm
- Serum was collected during each injection and 2 weeks after the last injection. Analysis of the humoral responses (antibodies against the glll protein) before and during the immunization was carried out by a seroneutralization test (test sensitive to mediation by the complement, see Bitsch and Eskilsen, curr Top Vet Med Anim Sci.
- IPMA test Immuno Peroxidase Monolayer Assay
- test serum diluted 2 in 2 in series in PBS was distributed in the wells and the plate was incubated for 1 hour at 37 ° C.
- the serum was removed and the plates were washed twice with PBS, followed of an hour's incubation in the presence of anti-porcine antibodies labeled with peroxidase (Nordic, Holland) and diluted 100 times in PBS After 1 hour, the plates were incubated in the presence of substrate 3 amino 9 ethylcarbazole (2 mg AEC in 10 ml of sodium acetate buffer (0 05 M at pH 5) and 75 ⁇ l of H 2 O 2 at 30%) The appearance of a red coloration is observed under an optical microscope The reaction was stopped after 15 minutes by 3 city water washes IPMA titers are calculated by taking the inverse of the highest dilution which causes a red coloration of the viral antigen foci on the infected cells
- IPMA antibody titer determined by the IPMA method
- results show that none of the unvaccinated animals developed antibodies against the PRV virus.
- the results indicate that even at the lowest vaccination dose, ie 3 x 75 ⁇ g, a humoral response was induced in 2 out of 3 pigs. Only one animal out of 3 reacted to a dosage of 560 ⁇ g
- Example 6 Induction of protection against a test with a virulent virus in pigs The protocol of example 5 is reproduced exactly. Three groups of 3 pigs aged 5 weeks were used. The animals come from a farm free from GRP. and of the same scope They are individually marked by a ring at the ear
- the virulent virus test was carried out according to the method described in Vaccine 1994, 12 (7), p 661 665 and is described below.
- the relative weight gain (RDWG) was calculated according to the formula below, in order to compare the performances of the three RDWG groups from the day of the test until day x day weight x weight on day of the test
- RDWG weight on the day of the test
- the nasal secretions of all the animals were taken with a swab every other day for 14 days after the test The weight of the nasal secretions taken was noted
- the nasal secretions taken were suspended in phosphate buffer. Decimal dilutions of these suspensions were inoculated into monolayer cell cultures, these cells coming from a continuous pig testicle (ST) cell line. Then, the presence of a cytological effect for these cell cultures was checked for five days.
- the lethal dose 50 was calculated according to the method of Reed and Muench (Amer. J. Hyg., 1938, 27, 493 497).
- the virus titers were expressed in TCID50 per gram of nasal secretion.
- the seroneutralizing antibody titers were observed between 64 and 128 for the animals belonging to the negative control group, between 128 and> 384 for the animals having received a dose of 75 ⁇ g of plasmid, and between 128 and 192 for animals having received a dose of 560 ⁇ g of plasmid
- the first viruses were isolated from the nasal secretions, two days after the test, for two of the three animals in each group.
- the titles virus reached a peak between the fourth and sixth day after the test, virus titers ranging between 10 ⁇ , 10 ⁇ 5 e t ' ⁇ TCID 50.
- the secretion of virus was stopped between the sixth and the eighth day after the test for the vaccinated animals, while it continued until the twelfth day after the test for the animals of the negative control group.
- the accessibility of the micro-organism can only be achieved by providing a sample to an expert designated by the applicant.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU11949/97A AU711915B2 (en) | 1995-12-21 | 1996-12-06 | Plasmid vaccine against pseudorabies virus |
EP96943118A EP0817799A1 (fr) | 1995-12-21 | 1996-12-06 | Vaccin plasmidique contre le virus pseudorabique |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE9501059 | 1995-12-21 | ||
BE9501059A BE1009826A3 (fr) | 1995-12-21 | 1995-12-21 | Vaccin plasmidique contre le virus pseudorabique. |
BE9600533A BE1010344A3 (fr) | 1996-06-12 | 1996-06-12 | Vaccin plasmidique contre le virus pseudorabique. |
BE9600533 | 1996-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997023502A1 true WO1997023502A1 (fr) | 1997-07-03 |
Family
ID=25663019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/005611 WO1997023502A1 (fr) | 1995-12-21 | 1996-12-06 | Vaccin plasmidique contre le virus pseudorabique |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0817799A1 (fr) |
AU (1) | AU711915B2 (fr) |
CA (1) | CA2216308A1 (fr) |
WO (1) | WO1997023502A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999037327A1 (fr) * | 1998-01-26 | 1999-07-29 | Sanofi Sante Nutrition Animale | Vaccin viral d'immunogenicite renforcee contre la maladie d'aujeszky |
US6207165B1 (en) | 1996-07-19 | 2001-03-27 | Merial | Polynucleotide formula against porcine reproductive and respiratory pathologies |
WO2002078732A1 (fr) * | 2001-02-15 | 2002-10-10 | The Registrar, Indian Institute Of Science | Nouvelle formulation de vaccin constituee d'un virus inactive de vaccin adn |
US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
US7078388B2 (en) | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
EP2572153B1 (fr) | 2010-05-17 | 2015-10-14 | Krauss-Maffei Wegmann GmbH & Co. KG | Système d'arme, procédé de tir et de détection de munitions |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110327461B (zh) * | 2019-07-17 | 2022-06-24 | 苏州世诺生物技术有限公司 | 一种猪伪狂犬病病毒亚单位疫苗的制备方法及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0261940A2 (fr) * | 1986-09-23 | 1988-03-30 | Applied Biotechnology, Inc. | Vaccins pseudorabiques et vecteurs d'ADN pour recombiner avec les poxvirus |
WO1991000359A1 (fr) * | 1989-06-26 | 1991-01-10 | Agracetus, Inc. | Transformation au moyen de particules de cellules somatiques animales |
WO1992003537A1 (fr) * | 1990-08-15 | 1992-03-05 | Therion Biologics Corporation | Particules de virus hybrides a replication defectueuse et auto-assemblees |
JPH05246888A (ja) * | 1991-09-03 | 1993-09-24 | Biseibutsu Kagaku Kenkyusho:Kk | コンポーネントワクチン |
-
1996
- 1996-12-06 AU AU11949/97A patent/AU711915B2/en not_active Ceased
- 1996-12-06 EP EP96943118A patent/EP0817799A1/fr not_active Withdrawn
- 1996-12-06 CA CA 2216308 patent/CA2216308A1/fr not_active Abandoned
- 1996-12-06 WO PCT/EP1996/005611 patent/WO1997023502A1/fr not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0261940A2 (fr) * | 1986-09-23 | 1988-03-30 | Applied Biotechnology, Inc. | Vaccins pseudorabiques et vecteurs d'ADN pour recombiner avec les poxvirus |
WO1991000359A1 (fr) * | 1989-06-26 | 1991-01-10 | Agracetus, Inc. | Transformation au moyen de particules de cellules somatiques animales |
WO1992003537A1 (fr) * | 1990-08-15 | 1992-03-05 | Therion Biologics Corporation | Particules de virus hybrides a replication defectueuse et auto-assemblees |
JPH05246888A (ja) * | 1991-09-03 | 1993-09-24 | Biseibutsu Kagaku Kenkyusho:Kk | コンポーネントワクチン |
Non-Patent Citations (4)
Title |
---|
COX G J M ET AL: "BOVINE HERPESVIRUS 1: IMMUNE RESPONSES IN MICE AND CATTLE INJECTED WITH PLASMID DNA", JOURNAL OF VIROLOGY, vol. 67, no. 9, 1 September 1993 (1993-09-01), pages 5664 - 5667, XP000574935 * |
DATABASE WPI Section Ch Week 9343, Derwent World Patents Index; Class B04, AN 93-339654, XP002026841 * |
MATSUDA TSUCHIDA, A. ET AL.: "Protection from Pseudorabies virus challenge in mice by a combination of purified gII, gIII and gVI antigens", J. VET. MED. SCI., vol. 54, no. 3, 1992, pages 447 - 452, XP000618878 * |
ROUSE, R. J. D. ET AL.: "Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding Herpes Simplex virus proteins", JOURNAL OF VIROLOGY, vol. 68, no. 9, September 1994 (1994-09-01), pages 5685 - 5689, XP000645186 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207165B1 (en) | 1996-07-19 | 2001-03-27 | Merial | Polynucleotide formula against porcine reproductive and respiratory pathologies |
US6576243B1 (en) | 1996-07-19 | 2003-06-10 | Merial | Polynucleotide vaccine formula against porcine reproductive and respiratory pathologies |
EP0912743B1 (fr) * | 1996-07-19 | 2005-09-28 | Merial | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
WO1999037327A1 (fr) * | 1998-01-26 | 1999-07-29 | Sanofi Sante Nutrition Animale | Vaccin viral d'immunogenicite renforcee contre la maladie d'aujeszky |
US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
US7078388B2 (en) | 2000-01-21 | 2006-07-18 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
WO2002078732A1 (fr) * | 2001-02-15 | 2002-10-10 | The Registrar, Indian Institute Of Science | Nouvelle formulation de vaccin constituee d'un virus inactive de vaccin adn |
EP2572153B1 (fr) | 2010-05-17 | 2015-10-14 | Krauss-Maffei Wegmann GmbH & Co. KG | Système d'arme, procédé de tir et de détection de munitions |
Also Published As
Publication number | Publication date |
---|---|
CA2216308A1 (fr) | 1997-07-03 |
AU711915B2 (en) | 1999-10-21 |
EP0817799A1 (fr) | 1998-01-14 |
AU1194997A (en) | 1997-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1294400B1 (fr) | Vaccin contre la fievre aphteuse | |
KR20210092762A (ko) | 아프리카 돼지 열병 바이러스에 대한 면역원성 조성물 | |
EP1232249B1 (fr) | Pneumovirus du canard et vaccins correspondants | |
KR101745029B1 (ko) | 재조합 조류 파라믹소바이러스 백신 및 이의 제조 및 사용 방법 | |
EA029470B1 (ru) | Способ стимулирования формирования защитного иммунитета против норовируса | |
WO2022007742A1 (fr) | Virus de pseudo-rage recombinant et composition de vaccin associée | |
CA3156263A1 (fr) | Agent pour induire l'immunite specifique contre le virus du syndrome respiratoire aigu severe (sras-cov-2) en forme liquide (variants) | |
JP7303306B2 (ja) | ***ウイルス様粒子抗原及びそのワクチン組成物並びに調製方法及び応用 | |
CN112625096B (zh) | 一种禽传染性支气管炎病毒样颗粒及其制备方法与应用 | |
EA036116B1 (ru) | Пестивирусные вакцины против врожденного тремора | |
WO1997023502A1 (fr) | Vaccin plasmidique contre le virus pseudorabique | |
CN111867622A (zh) | 经修饰的用于治疗布鲁氏菌病的布鲁氏菌疫苗株 | |
Aravind et al. | Protective effects of recombinant glycoprotein D based prime boost approach against duck enteritis virus in mice model | |
FR3012964A1 (fr) | Vaccins adjuves pour vaccination aviaire in ovo | |
JP2020537507A (ja) | パラミクソウイルス科の発現系 | |
BE1010344A3 (fr) | Vaccin plasmidique contre le virus pseudorabique. | |
CA2241280A1 (fr) | Pseudo-particules virales recombinantes et applications vaccinales et antitumorales | |
BE1009826A3 (fr) | Vaccin plasmidique contre le virus pseudorabique. | |
US10201604B2 (en) | Live attenuated infectious laryngotracheitis virus (ILTV) vaccines and preparation thereof | |
US4312947A (en) | Process for the preparation of a vaccine against panleucopenia of the cat | |
EP2640832B1 (fr) | Nouvel agent étiologique | |
KR102390674B1 (ko) | 개 아데노바이러스 2형 감염증 예방용 백신 조성물 | |
PT1721982E (pt) | Ácidos nucleicos e polipéptidos quiméricos de lissavírus | |
KR20230079021A (ko) | 약독화된 돼지 유행성 설사 바이러스 | |
Kumar et al. | Virus enhancement following infection with antibody-coated infectious bursal disease virus (IBDV) in chickens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996943118 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2216308 Country of ref document: CA Ref country code: CA Ref document number: 2216308 Kind code of ref document: A Format of ref document f/p: F |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1996943118 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97523273 Format of ref document f/p: F |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996943118 Country of ref document: EP |